Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Licenses Protein Crystallization Technology from Syrrx

NEW YORK, Feb. 3 (GenomeWeb News) - Microfluidics developer Fluidigm has obtained non-exclusive license rights to Syrrx's submicroliter protein crystallization technology, the companies said today.

The terms of the licensing agreement were not disclosed.

Syrrx said it obtained "broad patent protection" for the crystallization of proteins in submicroliter volumes through an exclusive license with Lawrence Berkeley National Laboratory. Fluidigm's non-exclusive license will provide it with freedom to operate relative to Syrrx's patent portfolio, the companies said.

Fluidigm said it acquired the license to support the commercialization of its Topaz protein crystallization platform, which relies on chips that consume only nanogram quantities of protein per trial.

David Weitz, Syrrx's general counsel, said in a statement that Fluidigm is the first system manufacturer to license the company's technology, and that Syrrx "looks forward to securing other licensees as submicroliter crystallization is more widely adopted."

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.